Response to Comment on: “Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?”

Eldad J. Dann

doi:10.3324/haematol.2026.301249

Comments

Response to Comment on: “Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?”

Eldad J. Dann

Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa

Haematologica Early view May 28, 2026 https://doi.org/10.3324/haematol.2026.301249

Abstract

Not available.

Figures & Tables

Article Information

Early view : Comments

DOI

https://doi.org/10.3324/haematol.2026.301249

Published

2026-05-28

Published By

Ferrata Storti Foundation, Pavia, Italy

Print ISSN

0390-6078

Online ISSN

1592-8721

Copyright & Usage

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views

19

PDF Downloads

27

No Data

PlumX

Response to Comment on: “Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?”

Abstract

Figures & Tables

Article Information

Article Usage

Download Citation

Navigate

For Authors

For Reviewers

For Advertisers

Education

Privacy

More